It seems I’m here again writing a post in response to an FDA announcement. Specifically, in response to the FDA announcing they’re delaying an announcement. And I’m honestly not surprised. As discussed in earlier posts, FDA’s delay of guidance on social media for pharma is, in some ways, understandable. In recent conversations with health digital thought leaders at SXSW, many of us are beginning to wonder if this is even FDA’s remit. Hear me out on this. The FDA is an agency founded to protect the public, and the guidelines around Rx brand communications that have been formed…
No Social Media Guidelines from FDA
April 4, 2011
Health Digital Check-Up: Content Curation in Healthcare
January 27, 2011
It’s pretty clear that 2011 is set to be the year of content as the focus shifts from the newest, shiniest, hippest platforms to the content that powers those channels. In today’s hyper fast, and hyperbolic, environment, it’s not just enough to come out high in search ratings – you need to deliver content for which your audience is looking.
Enter the boom of content curation sites and apps that are popping up across the digital landscape. Until now, these services have been free, but with the addition of newcomer Ongo (see “New Services Popping up Quickly”),…
FDA Delays Issuing Social Media Guidance until 2011
December 23, 2010
An open letter to the pharmaceutical industry:
This week we learned that the pharmaceutical industry needs to wait even longer for FDA guidance on social media marketing of drugs and devices when the Division of Drug Marketing, Advertising, and Communications (DDMAC) issued the following via email:
The Division of Drug Marketing, Advertising, and Communications (DDMAC) has been researching draft guidance topics on the following issues related to Internet/social media promotion of FDA-regulated medical products:
Responding to unsolicited requests
Fulfilling…
